Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under multiple stage studies for indications such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications including NSCLC, PDAC, CRC, and other solid tumors; JAV-8263, a BET inhibitor for solid and liquid tumors; JAB-2485 Aurora A inhibitor, JAB-30355 P53 Y220C inhibitor, JAB-BX102 CD73 mAb inhibitor, JAB-26766 PARP 7 inhibitor, and JAB-BX300 LIF inhibitor under trials for solid tumor indications; and JAB-24114, a glutamine-utilizing enzyme for solid tumor and hematological malignancy indications. The company also develops IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications. It has a collaboration agreement with Merck for cetuximab for combination trials. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.